Doheny Asset Management’s Kyntra Bio KYNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-322
Closed -$214K 99
2021
Q2
$214K Sell
322
-1,397
-81% -$805K 0.14% 94
2021
Q1
$1.49M Sell
1,719
-861
-33% -$917K 1.01% 33
2020
Q4
$2.39M Sell
2,580
-240
-9% -$252K 1.66% 18
2020
Q3
$2.9M Buy
2,820
+677
+32% +$728K 2.4% 8
2020
Q2
$2.17M Buy
2,143
+1,014
+90% +$942K 2.05% 17
2020
Q1
$1.21M Hold
1,129
0.96% 42
2019
Q4
$1.21M Buy
1,129
+119
+12% +$121K 0.96% 42
2019
Q3
$934K Sell
1,010
-449
-31% -$493K 0.81% 43
2019
Q2
$1.65M Buy
1,459
+24
+2% +$26.3K 1.38% 30
2019
Q1
$1.95M Sell
1,435
-895
-38% -$1.21M 1.66% 22
2018
Q4
$2.7M Buy
2,330
+309
+15% +$347K 1.97% 21
2018
Q3
$3.07M Sell
2,021
-14
-0.7% -$21.6K 1.61% 20
2018
Q2
$3.19M Sell
2,035
-1,305
-39% -$1.7M 1.73% 19
2018
Q1
$3.86M Buy
3,340
+1,713
+105% +$2.26M 2.03% 14
2017
Q4
$1.93M Sell
1,627
-410
-20% -$514K 0.9% 31
2017
Q3
$2.74M Buy
2,037
+700
+52% +$738K 1.26% 22
2017
Q2
$1.08M Buy
1,337
+211
+19% +$147K 0.51% 51
2017
Q1
$694K Sell
1,126
-6
-0.5% -$3.65K 0.31% 65
2016
Q4
$606K Buy
1,132
+12
+1% +$5.99K 0.29% 66
2016
Q3
$580K Buy
1,120
+343
+44% +$162K 0.3% 68
2016
Q2
$319K Buy
+777
New +$356K 0.16% 85

Other funds holding KYNB

Doheny Asset Management's KYNB Position: Q3 2021 in Review

Doheny Asset Management sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 322 shares — an estimated $214K sold.

Doheny Asset Management first reported a position in KYNB in Q2 2016 and held it in 21 quarters. The position peaked at $3.86M in Q1 2018. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

  • Doheny Asset Management reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
  • Doheny Asset Management sold 322 Kyntra Bio shares in Q3 2021, an estimated $214K.
  • Doheny Asset Management first reported a position in Kyntra Bio in Q2 2016 and held it in 21 quarters.
  • Doheny Asset Management's Kyntra Bio position peaked at $3.86M in Q1 2018.
  • 164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Doheny Asset Management's 13F filing for Q3 2021, filed 22 Oct 2021.